|Cyclacel Pharmaceuticals, Inc.|
200 Connell Drive
United States - Map
|Full Time Employees:||18|
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer and other serious diseases. The companys oncology development programs include sapacitabine, an orally-available nucleoside analogue for the treatment of hematological cancers and solid tumors; and seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2, -7 and -9, which are central to the process of cell division and cell cycle control. Its oncology development programs also comprise CYC065, an orally-available 2nd generation CDK-2, -5, and -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer; and Aurora kinase inhibitors, a serine/threonine protein kinases that focuses on cell division, or mitosis for the treatment of cancer. The companys non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
|Mr. Spiro George Rombotis ,
Chief Exec. Officer, Pres and Exec. Director
|Mr. Paul McBarron ,
Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer, Exec. VP of Fin. & Admin., Sec. and Exec. Director
|Dr. Judy H. Chiao M.D.,
Chief Medical Officer and VP of Clinical Devel. & Regulatory Affairs
|Prof. David Glover Ph.D., FRS FRSE,
|Dr. Susan Davis Ph.D.,
Director of Bus. Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|